Acacia subsidiary acquires rights to prescription lens technology patent portfolio

Acacia Research Corporation (Nasdaq:ACTG) announced today that a subsidiary has acquired rights to a patent portfolio for prescription lens technology.

“Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios”

"As Acacia's licensing success grows, an increasing number of technology companies are selecting us as their partner for the licensing of their patented technologies," commented Paul Ryan, Acacia Chairman and CEO. "Acacia is rapidly becoming the leader in technology licensing and we continue to grow our base of future revenues by adding new patent portfolios," concluded Mr. Ryan.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024